Skip to Content

First-line niraparib is associated with improvement in QA-PFS and QA-TWiST

According to the placebo-controlled trial PRIMA, patients with advanced ovarian cancer seem to benefit from the maintenance therapy with niraparib.

Ma Pilar Barretina-Ginesta

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top